Abstract
In the conference 'Hot Topics in Pharmacogenomics,' a joint meeting of the International Society of Pharmacogenomics and the Pacific Rim Association of Clinical Pharmacogenetics (Los Angeles, November 3–4, 2003, http://www.pharmacogenomics.org – full meeting report to follow), there was the presentation of dialectically opposite points of view on the impact of pharmacogenomics in clinical medicine. While Daniel Nebert (University of Cincinnati) stated that pharmacogenomics would not impact on clinical medicine, others such as Urs Meyer (University of Basel), Magnus Ingelman-Sundberg (Karolinska Institute), Richard Weinshilboum (Mayo Clinic), David Flockhart (Indiana University), Ronald Krauss (Lawrence Berkeley National Laboratory), Tamas Bartfai (Scripps Research Institute), and David Goldstein (University College London) were far more optimistic about the potential impact of pharmacogenomics on medical practice.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call